McClellan Mark B. 4

What Happened

• Mark B. McClellan, a director of Cigna Group (CI), was granted 782 shares on 2026-04-22. The Form 4 reports the acquisition as an award/grant (transaction code A) at a reported price of $0.00, i.e., a compensation issuance rather than a market purchase.

Key Details

• Transaction date: 2026-04-22; Filing date (Form 4): 2026-04-24.
• Transaction type/code: Award/Grant (A).
• Shares acquired: 782; Reported price per share: $0.00 (compensation grant); Total reported cash value: $0 (compensation issuance).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes/attachments: Exhibit 24 — Power of Attorney included in filing.
• Timeliness: Filed two days after the transaction date; appears to be timely under standard Form 4 reporting rules.

Context

• This was a compensation award (common for directors) rather than an open-market purchase; such grants are typically subject to vesting or other restrictions and do not necessarily indicate the insider bought or sold stock with personal funds.
• For retail investors: awards are routine director compensation and should be interpreted differently than outright purchases or sales when assessing insider sentiment.